Montelukast Teva (Montelukast Sodium)

Montelukast, the active ingredient in Montelukast Teva, is a leukotriene receptor antagonist presented as an oral tablet for oral use. It is used to manage asthma, allergic rhinitis and exercise‑induced bronchoconstriction in adults and children. GNH USA supplies Montelukast Teva as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Montelukast acts on the leukotriene pathway to control inflammatory airway conditions. - Asthma: improves symptom control and reduces the frequency of exacerbations in persistent asthma. - Allergic rhinitis: alleviates nasal congestion, sneezing and itching caused by seasonal or perennial allergens. - Exercise‑induced bronchoconstriction: prevents airway narrowing that occurs during or after physical activity.

Montelukast is generally well tolerated, but adverse reactions can occur.

Common Side Effects: - Headache: mild to moderate intensity, often transient. - Abdominal pain: discomfort in the stomach region, usually self‑limiting. - Cough: occasional dry cough without infection. - Nausea: feeling of queasiness, may resolve with continued therapy.

Serious or Rare Side Effects: - Angioedema: swelling of face, lips or throat requiring urgent care. - Mood changes: depression, anxiety, or unusual behavior. - Suicidal thoughts: rare but necessitates immediate medical attention.

Montelukast should be used with awareness of specific safety considerations. - Pregnancy: consult a healthcare professional; safety data are limited. - Breastfeeding: weigh potential benefits against possible risks to the infant. - Hepatic impairment: use with caution; monitor liver function if clinically indicated. - Concomitant phenobarbital or rifampin: may reduce drug exposure, consider alternative therapy. - Store at below 25°C: keep in the original packaging, protect from moisture and direct sunlight.

Montelukast may interact with other medicines, requiring attention to potential effects.

Major Interactions (Avoid): - Phenobarbital: can lower montelukast plasma levels, reducing efficacy. - Rifampin: may decrease therapeutic effect by enhancing metabolism.

Moderate Interactions (Monitor Closely): - Warfarin: possible increase in INR; monitor coagulation parameters. - Beta‑agonists: additive bronchodilation may occur; assess clinical response. - Antidepressants: monitor for mood alterations or worsening depression.